A case of reversible pulmonary arterial hypertension associated with incontinentia pigmenti

被引:8
作者
Atallah, Veronique [1 ]
Meot, Mathilde [1 ]
Kossorotoff, Manoelle [2 ]
Galmiche-Rolland, Louise [3 ]
Lardeux, Claude [1 ]
Neven, Benedicte [4 ]
Bodemer, Christine [5 ,6 ]
Bonnet, Damien [1 ,6 ]
机构
[1] Necker Enfants Malades Hosp, Dept Pediat Cardiol, 149 Rue Sevres, F-75015 Paris, France
[2] Necker Enfants Malades Hosp, Dept Pediat Neurol, Paris, France
[3] Necker Enfants Malades Hosp, Dept Pathol, Paris, France
[4] Necker Enfants Malades Hosp, Dept Immunol, Paris, France
[5] Necker Enfants Malades Hosp, Natl Reference Ctr Genodermatoses MAGEC, Dept Dermatol, Paris, France
[6] Univ Paris 05, PRES Sorbonne Paris, Imagine Inst, UMR 1163, Paris, France
关键词
Pulmonary arterial hypertension; pulmonary hypertension; genetics/genomics/epigenetics; pediatrics; pediatric cardiovascular disease; DEFICIENCY; GIRL;
D O I
10.1177/2045894018793983
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Incontinentia pigmenti (IP) is a multisystemic disorder in which pulmonary arterial hypertension (PAH) is a severe and rarely reported association. The prognosis has been poor in reported cases. In our patient, IP was diagnosed during the neonatal period with a combination of cutaneous, ophthalmic, and neurological symptoms. The infant experienced severe collapse with bradycardia during general anesthesia to treat retinal telangiectasia. Echocardiography after resuscitation revealed suprasystemic pulmonary hypertension (PH). Right heart catheterization (RHC) confirmed precapillary PAH not responding to acute vasodilatation test. Lung biopsy was performed to exclude alveolo-capillary dysplasia. Upfront triple therapy with endothelin receptor antagonist, PDE5 inhibitors, and prostacyclin was started. Due to a potential inflammatory mechanism of this acute PAH in the setting of IP, TNF-alpha blockers and steroids were associated. The evolution was favorable with progressive normalization of the pulmonary artery pressure confirmed by RHC after six months. Doses of PAH drugs were tapered down, and finally all PAH treatments could be stopped after 18 months. Subsequent controls including physical exams and echocardiograms did not show signs of PH. This unusual reversible case of pediatric PAH without associated congenital heart disease or portal hypertension highlights the potential reversibility of pediatric PH when an inflammatory mechanism can be suspected. This is the first reported case of non-fatal isolated PAH associated with IP.
引用
收藏
页数:3
相关论文
共 10 条
[1]   Pulmonary hypertension and vasculopathy in incontinentia pigmenti: a case report [J].
Alshenqiti, Abduljabbar ;
Nashabat, Marwan ;
AlGhoraibi, Hissah ;
Tamimi, Omar ;
Alfadhel, Majid .
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2017, 13 :629-634
[2]   Unusual neonatal presentation of incontinentia pigmenti with persistent pulmonary hypertension of the newborn: A case report [J].
Godambe S. ;
McNamara P. ;
Rajguru M. ;
Hellmann J. .
Journal of Perinatology, 2005, 25 (4) :289-292
[3]   Unilateral acheiria and fatal primary pulmonary hypertension in a girl with incontinentia pigmenti [J].
Hayes, IM ;
Varigos, G ;
Upjohn, EJ ;
Orchard, DC ;
Penny, DJ ;
Savarirayan, R .
AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2005, 135A (03) :302-303
[4]   Incontinentia pigmenti: a case associated with cardiovascular anomalies [J].
Miteva, L ;
Nikolova, A .
PEDIATRIC DERMATOLOGY, 2001, 18 (01) :54-56
[5]   New Insight Into the Pathogenesis of Cerebral Small-Vessel Diseases [J].
Mueller, Kristin ;
Courtois, Gilles ;
Ursini, Matilde Valeria ;
Schwaninger, Markus .
STROKE, 2017, 48 (02) :520-527
[6]   Skin lesion development in a mouse model of incontinentia pigmenti is triggered by NEMO deficiency in epidermal keratinocytes and requires TNF signaling [J].
Nenci, A ;
Huth, M ;
Funteh, A ;
Schmidt-Supprian, M ;
Bloch, W ;
Metzger, D ;
Chambon, P ;
Rajewsky, K ;
Krieg, T ;
Haase, I ;
Pasparakis, M .
HUMAN MOLECULAR GENETICS, 2006, 15 (04) :531-542
[7]   A nuclear factor-κB inhibitor pyrrolidine dithiocarbamate ameliorates pulmonary hypertension in rats [J].
Sawada, Hirofumi ;
Mitani, Yoshihide ;
Maruyama, Junko ;
Jiang, Bao Hua ;
Ikeyama, Yukiko ;
Dida, Francis A. ;
Yamamoto, Hatsumi ;
Imanaka-Yoshida, Kyoko ;
Shimpo, Hideto ;
Mizoguchi, Akira ;
Maruyama, Kazuo ;
Komada, Yoshihiro .
CHEST, 2007, 132 (04) :1265-1274
[8]   Bone Morphogenetic Protein Receptor Type II Deficiency and Increased Inflammatory Cytokine Production [J].
Soon, Elaine ;
Crosby, Alexi ;
Southwood, Mark ;
Yang, Peiran ;
Tajsic, Tamara ;
Toshner, Mark ;
Appleby, Sarah ;
Shanahan, Catherine M. ;
Bloch, Kenneth D. ;
Pepke-Zaba, Joanna ;
Upton, Paul ;
Morrell, Nicholas W. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 192 (07) :859-872
[9]  
TRIKI C, 1992, REV NEUROL, V148, P773
[10]   Fatal pulmonary arterial hypertension in an infant girl with incontinentia pigmenti [J].
Yasuda, Kenji ;
Minami, Noriaki ;
Yoshikawa, Yoko ;
Taketani, Takeshi ;
Fukuda, Seiji ;
Yamaguchi, Seiji .
PEDIATRICS INTERNATIONAL, 2016, 58 (05) :394-396